Is Stryker Corporation (SYK) overvalued or fairly valued?

MarketChacha shows Stryker Corporation's valuation in context — a trailing P/E of about 31.4, a forward P/E of about 18.1, a price-to-book of about 4.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Stryker Corporation's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.38×) from reported figures — education, not a rating.

What is Stryker Corporation's revenue?

Stryker Corporation reported revenue of $25.1B for FY2025, with net profit of $3.2B, per official filings.

What is the share price of Stryker Corporation (SYK)?

Stryker Corporation last traded at $303.13 (-1.6% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Stryker Corporation

SYK · NYSE · Healthcare · United States

Snapshot

TickerSYK

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees56,000

HeadquartersPortage, United States

Websitewww.stryker.com

Filings tracked18

About Stryker Corporation

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Who owns it

Insiders5.4%
Institutions82.8%
Public & other11.8%

3,049 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.7.15%
Vanguard Capital Management LLC5.88%
JPMORGAN CHASE & CO4.50%
State Street Corporation4.05%
Greenleaf Trust3.97%
Price (T.Rowe) Associates Inc3.11%
Vanguard Portfolio Management LLC2.13%
Wellington Management Group, LLP2.13%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 2.5 points over the period — profitability is trending down.

Cash conversion1.38×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend15.4% → 12.9%

Margin has compressed by about 2.5 points over the period — profitability is trending down.

Growth qualityrev 11% · PAT 1%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $8.0B · EPS 5.15

Est. earnings growth +15.3%

Next fiscal year

Rev $29.7B · EPS 16.75

Est. earnings growth +11.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$25.1B

Net margin

12.9%

ROE

14.5%

Revenue CAGR (2y)

+10.7%

Profit CAGR (2y)

+1.3%

EPS (FY2025)

8.40

Net profit (FY2025)

$3.2B

Ask MarketChacha about SYK

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$25.1B	$3.2B	8.40	12.9%	14.5%
FY2024	$22.6B	$3.0B	7.76	13.2%	14.5%
FY2023	$20.5B	$3.2B	8.25	15.4%	17.0%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$6.6B	$1.3B	3.30	19.4%
2026Q1	$6.0B	$745.0M	1.93	12.4%
2025Q4	$7.2B	$849.0M	2.20	11.8%
2025Q3	$6.1B	$859.0M	2.22	14.2%
2025Q2	$6.0B	$884.0M	2.29	14.7%
2025Q1	$5.9B	$654.0M	1.69	11.1%
2024Q4	$6.4B	$546.0M	1.41	8.5%
2024Q3	$5.5B	$834.0M	2.16	15.2%
2024Q2	$5.4B	$825.0M	2.14	15.2%
2024Q1	$5.2B	$788.0M	2.05	15.0%
2023Q4	$5.8B	$1.1B	2.98	19.7%
2023Q3	$4.9B	$692.0M	1.80	14.1%
2023Q2	$5.0B	$738.0M	1.93	14.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/31/2026
8-K — Results of operations, Exhibits
SEC7/30/2026material
8-K — Other events, Exhibits
SEC6/26/2026material
8-K — Executive/director change, Exhibits
SEC5/20/2026material
10-Q filing
SEC5/11/2026
8-K — Shareholder vote results
SEC5/8/2026material
8-K — Results of operations, Exhibits
SEC4/30/2026material
8-K/A — Reg FD disclosure
SEC4/9/2026
8-K — Reg FD disclosure, Exhibits
SEC3/23/2026material
8-K — Reg FD disclosure
SEC3/12/2026material
8-K — Other events
SEC3/11/2026material
10-K filing
SEC2/11/2026
8-K — Results of operations, Exhibits
SEC1/29/2026material

2025

8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC12/4/2025material
10-Q filing
SEC10/31/2025
8-K — Results of operations, Exhibits
SEC10/30/2025material
10-Q filing
SEC8/1/2025
8-K — Results of operations, Exhibits
SEC7/31/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.